Get the Stockscreener App
25.24
2.73%
0.67
After Hours:
25.19
-0.05
-0.20%
Agios Pharmaceuticals Inc stock is traded at $25.24, with a volume of 3.64M.
It is up +2.73% in the last 24 hours and down -41.91% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
See More
Previous Close:
$24.57
Open:
$24.66
24h Volume:
3.64M
Relative Volume:
3.44
Market Cap:
$1.47B
Revenue:
$32.87M
Net Income/Loss:
$674.31M
P/E Ratio:
2.2218
EPS:
11.36
Net Cash Flow:
$-330.11M
1W Performance:
-42.18%
1M Performance:
-41.91%
6M Performance:
-16.17%
1Y Performance:
-54.56%
1-Day Range:
$23.00
$25.94
1-Week Range:
$22.24
$46.00
52-Week Range:
$22.24
$62.45
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
25.24 | 1.43B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios rebounds as Leerink upgrades to Outperform on selloff - MSN
Why Agios Plummeted, Losing Half Its Value, While Fulcrum Surged - MSN
AGIO: JP Morgan Lowers Price Target to $20.00 -- Maintains Neutral Rating | AGIO Stock News - GuruFocus
Agios Pharma stock price target lowered to $48 at H.C. Wainwright on mixed trial data - Investing.com Canada
Leerink Partners upgrades Agios Pharma stock on thalassemia potential By Investing.com - Investing.com Canada
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results - sharewise.com
How Recent Events Are Reshaping the Agios Pharmaceuticals Investment Story - Yahoo Finance
Agios slumps on mixed Phase III trial of mitapivat in sickle cell disease - The Pharma Letter
Agios stock rebounds as Leerink upgrades (AGIO:NASDAQ) - Seeking Alpha
Will Agios Pharmaceuticals Inc. (8AP) stock beat growth indexesStock Surge & Safe Capital Allocation Plans - newser.com
Agios Pharmaceuticals Stock Suffers Record Wipeout As Wall Street Warns Of 'Uncertain' Regulatory Path For Sickle Cell Drug - Stocktwits
Agios Pharma stock plunges on mixed Pyrukynd sickle cell trial results - Investing.com India
AGIO: Leerink Partners Upgrades Rating, Lowers Price Target | AG - GuruFocus
AGIO: Goldman Sachs Lowers Price Target, Maintains Neutral Ratin - GuruFocus
Leerink Partners upgrades Agios Pharma stock on thalassemia potential - Investing.com India
Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs - TipRanks
Agios Pharmaceuticals (AGIO) Receives Upgrade Despite Mixed Tria - GuruFocus
Nvidia To Rally Around 72%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
RBC Downgrades Agios Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $28 From $57 - MarketScreener
Leerink Partners Upgrades Agios Pharmaceuticals to Outperform From Market Perform, PT is $34 - MarketScreener
AGIO: HC Wainwright Lowers Price Target But Maintains Buy Rating - GuruFocus
Published on: 2025-11-20 04:28:25 - newser.com
Published on: 2025-11-20 00:18:11 - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock moves on employment dataJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
Published on: 2025-11-19 21:36:35 - newser.com
Will Agios Pharmaceuticals Inc. (8AP) stock hit analyst forecasts - newser.com
How Agios Pharmaceuticals Inc. (8AP) stock correlates with oil marketsOil Prices & Fast Entry and Exit Trade Plans - newser.com
Published on: 2025-11-19 18:19:52 - newser.com
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results By Investing.com - Investing.com South Africa
Agios Makes Case For Pyrukynd Approval In SCD Despite Mixed Phase III Results - Citeline News & Insights
Will Agios Pharmaceuticals Inc. stock see PE expansionProduct Launch & High Return Trade Opportunity Guides - newser.com
Agios Pharmaceuticals Plunges Over 50% as Sickle Cell Drug Delivers Mixed Phase 3 Results - FinancialContent
Agios planning sNDA on mixed sickle cell data for mitapivat - BioWorld MedTech
This Biotech Just Lost Half Its Value As Its Rival Celebrated - Investor's Business Daily
Agios reports mixed results in sickle cell disease trial of mitapivat - Investing.com Nigeria
Agios Pharma: Study Fail May Affect Mitapivat TDT ApprovalExpect More Volatility (AGIO) - Seeking Alpha
Agios Pharma stock price target cut to $32 from $54 at BofA on SCD trial results - Investing.com UK
Agios Shares Plunge 50% After Mixed Phase 3 RISE UP Results For Mitapivat - Nasdaq
Why Shares in Agios Pharmaceuticals Got Crushed Today - AOL.com
Agios Pharmaceuticals (AGIO) Faces Downgrade Amid Sickle Cell Drug Data - GuruFocus
Agios Pharma stock rating downgraded by RBC Capital after mixed trial data - Investing.com
Why Shares in Agios Pharmaceuticals Got Crushed Today - The Motley Fool
RBC downgrades Agios to Sector Perform after mitapivat ‘falls short’ - TipRanks
Agios Pharmaceuticals (AGIO) Faces Uncertainty After Trial Resul - GuruFocus
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results - Benzinga
Agios Pharmaceuticals (AGIO) Sees Sharp Decline in Stock Price - GuruFocus
Agios shares fall on mixed sickle cell results for blood disease drug - BioPharma Dive
Why Is Agios Pharmaceuticals Stock Sinking Today? - Benzinga
Agios shares tumble on mixed results for sickle cell drug trial - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Agios hit as mitapivat delivers mixed data in pivotal sickle cell study - FirstWord Pharma
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):